Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
The limited understanding of the heterogeneity in the treatment response to antidiabetic drugs contributes to metabolic deterioration and cardiovascular complications 1,2, stressing the need for more personalized treatment 1. Although recent attempts have been made to classify diabetes into subgroups, the utility of such stratification in predicting treatment response is unknown 3. We enrolled par
